Abstract:AbstractBackgroundHistone deacetylases (HDACs) engage in the regulation of various cellular processes by controlling global gene expression. The dysregulation of HDACs leads to carcinogenesis, making HDACs ideal targets for cancer therapy. However, the use of HDAC inhibitors (HDACi) as single agents has been shown to have limited success in treating solid tumors in clinical studies. This study aimed to identify a novel downstream effector of HDACs to provide a potential target for combination therapy.MethodsTranscriptome sequencing and bioinformatics analysis were performed to screen for genes responsive to HDACi in breast cancer cells. The effects of HDACi on cell viability were detected using the MTT assay. The mRNA and protein levels of genes were determined by quantitative reverse transcription‐PCR (qRT‐PCR) and Western blotting. Cell cycle distribution and apoptosis were analyzed by flow cytometry. The binding of CREB1 (cAMP‐response element binding protein 1) to the promoter of the KDELR (The KDEL (Lys‐Asp‐Glu‐Leu) receptor) gene was validated by the ChIP (chromatin immunoprecipitation assay). The association between KDELR2 and protein of centriole 5 (POC5) was detected by immunoprecipitation. A breast cancer‐bearing mouse model was employed to analyze the effect of the HDAC3‐KDELR2 axis on tumor growth.ResultsKDELR2 was identified as a novel target of HDAC3, and its aberrant expression indicated the poor prognosis of breast cancer patients. We found a strong correlation between the protein expression patterns of HADC3 and KDELR2 in tumor tissues from breast cancer patients. The results of the ChIP assay and qRT‐PCR analysis validated that HDAC3 transactivated KDELR2 via CREB1. The HDAC3‐KDELR2 axis accelerated the cell cycle progression of cancer cells by protecting the centrosomal protein POC5 from proteasomal degradation. Moreover, the HDAC3‐KDELR2 axis promoted breast cancer cell proliferation and tumorigenesis in vitro and in vivo.ConclusionOur results uncovered a previously unappreciated function of KDELR2 in tumorigenesis, linking a critical Golgi‐the endoplasmic reticulum traffic transport protein to HDAC‐controlled cell cycle progression on the path of cancer development and thus revealing a potential therapeutical target for breast cancer.

A Novel Histone Deacetylase Pathway Regulates Mitosis by Modulating Aurora B Kinase Activity.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Dna-Pkcs Inhibition Impairs Hdac6-Mediated Hsp90 Chaperone Function On Aurora A And Enhances Hdacs Inhibitor-Induced Cell Killing By Increasing Mitotic Aberrant Spindle Assembly

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Dissecting the Roles of Haspin and VRK1 in Histone H3 Phosphorylation During Mitosis.

An Overview of HDAC Inhibitors and Their Synthetic Routes.

A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling

Cyclic Peptide Histone Deacetylase Inhibitors

Histone deacetylases and cancer: causes and therapies

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.

New Development of HDAC Inhibitors As Anti-Cancer Agents

Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker

Histone Deacetylase Inhibitors as Anticancer Drugs

KDELR2 Promotes Breast Cancer Proliferation Via HDAC3‐mediated Cell Cycle Progression

Histone Deacetylase Inhibitors Merged with Protein Tyrosine Kinase Inhibitors.

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Hdac1/3 Dual Selective Inhibitors - New Therapeutic Agents For The Potential Treatment Of Cancer

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.